

Figure S1 Survival rates of patients with different levels of CD8+T counts under different treatments.



**Notes:** The difference in the survival rates of patients with different levels of CD8+T cell counts under TACE (A), RFA (B) and TACE + RFA (C) in the total cohort; Survival rates of patients with different levels of CD8+T cell counts under TACE (D), RFA (E) and TACE + RFA (F) in the training cohort; Survival rates of patients with different levels of CD8+T cell counts under TACE (G), RFA (H) and TACE + RFA (I) in the validation cohort. **Abbreviations:** TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation.

Figure S2 The changes of each modeling index at 1-year follow-up.



Notes: (A) aspartate aminotransferase (AST); (B) alpha fetoprotein (AFP);(C) CD8+T cell counts;(D) C-reactive protein (CRP).